Exosome Therapeutics
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
18
NCT05843799
A Study to Evaluate the Safety and Tolerability of ILB-202
Phase: Phase 1
Role: Lead Sponsor
Start: May 16, 2023
Completion: Oct 4, 2023
Loading map...